|
|
|
|
|
Escitalopram: profile and news
Forest Laboratories Receives Patent Term Extension for Lexapro Mar 4, 2006 Lundbeck deviates from 2006 financial target due to reduction in ... Feb 7, 2006 Forest Laboratories Receives Patent Term Extension for Lexapro Mar 2, 2006 Trimipramine for Refractory Panic Attacks Mar 2, 2006 Cipralex® - new data supports the superiority of Cipralex® ... Feb 27, 2006 CORRECTION Lundbeck won't reach planned 2006 opg growth of 12 pct Feb 7, 2006 Replidyne and Forest Laboratories Announce FDA Acceptance for ... Feb 23, 2006 Replidyne and Forest Laboratories Announce FDA Acceptance for ... Feb 23, 2006 Danish shares close lower, led by H Lundbeck, AP Moeller-Maersk ... Feb 7, 2006 Depression - Symptoms, Causes and Treatment options Feb 15, 2006 Myocarditis During Clozapine Treatment Feb 14, 2006 Replidyne and Forest Laboratories Announce Faropenem Medoxomil ... Feb 13, 2006 The Leading Antidepressant Firms Will Face Strong Competition Due ... Feb 2, 2006 Lundbeck won't reach planned 2006 opg growth of 12 pct on low ... Feb 7, 2006 The Leading Antidepressant Firms Will Face Strong Competition Due ... Feb 2, 2006 Forest Laboratories, Inc. Reports Q3'06 Diluted Earnings Per Share ... Jan 17, 2006 Mylan Laboratories and Forest Laboratories Announce Nebivolol ... Jan 12, 2006 Clinical Guidelines for Psychiatrists for the Use of ... Jan 23, 2006 Cipralex®; effective in treatment of Obsessive-Compulsive ... Nov 14, 2005 Bupropion re-kindles interest in dopamine strategy for major ... Nov 12, 2005 Gedeon Richter and Forest Laboratories Expand Relationship with ... Nov 28, 2005 Gedeon Richter and Forest Laboratories Expand Relationship with ... Nov 28, 2005 Advertisements for SSRI antidepressants are misleading Nov 12, 2005 New Study Compared Sexual Functioning of Patients Treated with ... Nov 10, 2005 Ads for SSRI antidepressants are misleading, say researchers Nov 11, 2005 H.Lundbeck A/S-Interim report for the third quarter of 2005 Nov 9, 2005 Advertisements for SSRIs May Be Misleading Nov 8, 2005 Antidepressant Ads Misleading Nov 8, 2005 Escitalopram for social anxiety disorder Sep 29, 2005 International Approvals: Tarceva, Cipralex, Keppra Sep 26, 2005 IVAX Not In Negotiations Regarding A Lexapro Settlement Oct 5, 2005 Ivax: Not negotiating on Lexapro Oct 6, 2005 Ivax denies rumour it is in talks on patent dispute settlement ... Oct 6, 2005 Forest Laboratories and Lundbeck Enter Into Settlement Agreement ... Oct 6, 2005 Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce ... Sep 28, 2005 New Survey Results from the Community Anti-Drug Coalitions of ... Sep 29, 2005 Second-Generation Antidepressants Equally Effective Sep 20, 2005 Antidepressants, Depression and Suicide Sep 12, 2005 Breaking the Teeth -- Grinding Habit Sep 22, 2005 Many meds don't mix with the sun Sep 21, 2005 Merrimack County Superior Court Log Sep 23, 2005 Drug combo backed for high BP Sep 14, 2005 Treating both insomnia and depression Sep 13, 2005 Stanford Study Evaluates Combined Treatment of Insomnia and ... Sep 7, 2005 Escitalopram for social anxiety disorder Aug 31, 2005 Prognosis of Depression in Old Age Compared to Middle Age: A ... Aug 31, 2005 Forest Laboratories Updates Lexapro Patent Litigation Status Aug 26, 2005 Forest Laboratories Updates Lexapro Patent Litigation Status Aug 26, 2005 Oral Solution Formulation of Namenda(R), the Only FDA-Approved ... Aug 18, 2005 Oral Solution Formulation of Namenda(R), the Only FDA-Approved ... Aug 18, 2005 Amelioration of Erectile Dysfunction Following a Switch From ... Aug 12, 2005 Other information Indication For the treatment of major depressive disorder and Generalized Anxiety Disorder (GAD). Pharmacology Escitalopram is one of a class of antidepressants known as selective serotonin reuptake inhibitors (SSRIs). It is used to treat the depression associated with mood disorders. It is also used on occassion in the treatment of body dysmorphic disorder and anxiety. The antidepressant, antiobsessive-compulsive, and antibulimic actions of escitalopram are presumed to be linked to its inhibition of CNS neuronal uptake of serotonin. In vitro studies show that escitalopram is a potent and selective inhibitor of neuronal serotonin reuptake and has only very weak effects on norepinephrine and dopamine neuronal reuptake. Escitalopram has no significant affinity for adrenergic (alpha1, alpha2, beta), cholinergic, GABA, dopaminergic, histaminergic, serotonergic (5HT1A, 5HT1B, 5HT2), or benzodiazepine receptors; antagonism of such receptors has been hypothesized to be associated with various anticholinergic, sedative, and cardiovascular effects for other psychotropic drugs. The chronic administration of escitalopram was found to downregulate brain norepinephrine receptors, as has been observed with other drugs effective in the treatment of major depressive disorder. Escitalopram does not inhibit monoamine oxidase. Mechanism Of Action The antidepressant, antiobsessive-compulsive, and antibulimic actions of escitalopram are presumed to be linked to its inhibition of CNS neuronal uptake of serotonin. Escitalopram blocks the reuptake of serotonin at the serotonin reuptake pump of the neuronal membrane, enhancing the actions of serotonin on 5HT1A autoreceptors. SSRIs bind with significantly less affinity to histamine, acetylcholine, and norepinephrine receptors than tricyclic antidepressant drugs. Drug Category Antidepressive Agents, Second-Generation; Serotonin Uptake Inhibitors; ATC:N06AB10 Brand Names/Synonyms Escitalopram; Escitalopram Oxalate; Escitalopram [Inn]; Lexapro Dosage Forms TABLET Absorption The absolute bioavailability of citalopram is about 80% relative to an intravenous dose Interactions -->Interactions for Escitalopram: CNS Drugs - Given the primary CNS effects of escitalopram, caution should be used when it is taken in combination with other centrally acting drugs. Alcohol - Although LEXAPRO did not potentiate the cognitive and motor effects of alcohol in a clinical trial, as with other psychotropic medications, the use of alcohol by patients taking LEXAPRO is not recommended. Monoamine Oxidase Inhibitors (MAOIs) - See Contraindications and Warnings. Drugs That Interfere With Hemostasis (NSAIDs, Aspirin, Warfarin, etc.) Serotonin release by platelets plays an important role in hemostasis. Epidemiological studies of the case-control and cohort design that have demonstrated an association between use of psychotropic drugs that interfere with serotonin reuptake and the occurrence of upper gastrointestinal bleeding have also shown that concurrent use of an NSAID or aspirin potentiated the risk of bleeding. Thus, patients should be cautioned about the use of such drugs concurrently with LEXAPRO. Cimetidine - In subjects who had received 21 days of 40 mg/day racemic citalopram, combined administration of 400 mg/day cimetidine for 8 days resulted in an increase in citalopram AUC and Cmax of 43% and 39%, respectively. The clinical significance of these findings is unknown. Digoxin - In subjects who had received 21 days of 40 mg/day racemic citalopram, combined administration of citalopram and digoxin (single dose of 1 mg) did not significantly affect the pharmacokinetics of either citalopram or digoxin. Lithium - Coadministration of racemic citalopram (40 mg/day for 10 days) and lithium (30 mmol/day for 5 days) had no significant effect on the pharmacokinetics of citalopram or lithium. Nevertheless, plasma lithium levels should be monitored with appropriate adjustment to the lithium dose in accordance with standard clinical practice. Because lithium may enhance the serotonergic effects of escitalopram, caution should be exercised when LEXAPRO and lithium are coadministered. Pimozide and Celexa - In a controlled study, a single dose of pimozide 2 mg co-administered with racemic citalopram 40 mg given once daily for 11 days was associated with a mean increase in QTc values of approximately 10 msec compared to pimozide given alone. Racemic citalopram did not alter the mean AUC or Cmax of pimozide. The mechanism of this pharmacodynamic interaction is not known. Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan. If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised. Theophylline - Combined administration of racemic citalopram (40 mg/day for 21 days) and the CYP1A2 substrate theophylline (single dose of 300 mg) did not affect the pharmacokinetics of theophylline. The effect of theophylline on the pharmacokinetics of citalopram was not evaluated. Warfarin - Administration of 40 mg/day racemic citalopram for 21 days did not affect the pharmacokinetics of warfarin, a CYP3A4 substrate. Prothrombin time was increased by 5%, the clinical significance of which is unknown. Carbamazepine - Combined administration of racemic citalopram (40 mg/day for 14 days) and carbamazepine (titrated to 400 mg/day for 35 days) did not significantly affect the pharmacokinetics of carbamazepine, a CYP3A4 substrate. Although trough citalopram plasma levels were unaffected, given the enzyme-inducing properties of carbamazepine, the possibility that carbamazepine might increase the clearance of escitalopram should be considered if the two drugs are coadministered. Triazolam - Combined administration of racemic citalopram (titrated to 40 mg/day for 28 days) and the CYP3A4 substrate triazolam (single dose of 0.25 mg) did not significantly affect the pharmacokinetics of either citalopram or triazolam. Ketoconazole - Combined administration of racemic citalopram (40 mg) and ketoconazole (200 mg) decreased the Cmax and AUC of ketoconazole by 21% and 10%, respectively, and did not significantly affect the pharmacokinetics of citalopram. Ritonavir - Combined administration of a single dose of ritonavir (600 mg), both a CYP3A4 substrate and a potent inhibitor of CYP3A4, and escitalopram (20 mg) did not affect the pharmacokinetics of either ritonavir or escitalopram. CYP3A4 and -2C19 Inhibitors - In vitro studies indicated that CYP3A4 and -2C19 are the primary enzymes involved in the metabolism of escitalopram. However, coadministration of escitalopram (20 mg) and ritonavir (600 mg), a potent inhibitor of CYP3A4, did not significantly affect the pharmacokinetics of escitalopram. Because escitalopram is metabolized by multiple enzyme systems, inhibition of a single enzyme may not appreciably decrease escitalopram clearance. Drugs Metabolized by Cytochrome P4502D6 - In vitro studies did not reveal an inhibitory effect of escitalopram on CYP2D6. In addition, steady state levels of racemic citalopram were not significantly different in poor metabolizers and extensive CYP2D6 metabolizers after multiple-dose administration of citalopram, suggesting that coadministration, with escitalopram, of a drug that inhibits CYP2D6, is unlikely to have clinically significant effects on escitalopram metabolism. However, there are limited in vivo data suggesting a modest CYP2D6 inhibitory effect for escitalopram, i.e., coadministration of escitalopram (20 mg/day for 21 days) with the tricyclic antidepressant desipramine (single dose of 50 mg), a substrate for CYP2D6, resulted in a 40% increase in Cmax and a 100% increase in AUC of desipramine. The clinical significance of this finding is unknown. Nevertheless, caution is indicated in the coadministration of escitalopram and drugs metabolized by CYP2D6. Metoprolol - Administration of 20 mg/day LEXAPRO for 21 days in healthy volunteers resulted in a 50% increase in Cmax and 82% increase in AUC of the beta-adrenergic blocker metoprolol (given in a single dose of 100 mg). Increased metoprolol plasma levels have been associated with decreased cardioselectivity. Coadministration of LEXAPRO and metoprolol had no clinically significant effects on blood pressure or heart rate. Electroconvulsive Therapy (ECT) - There are no clinical studies of the combined use of ECT and escitalopram. Concomitant Administration with Racemic Citalopram Citalopram - Since escitalopram is the active isomer of racemic citalopram (Celexa), the two agents should not be coadministered. Chemical IUPAC Name 1-(3-dimethylaminopropyl)-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile Chemical Formula C20H21FN2O Half Life 27-32 hours Drug Type Approved Drug # Accession No APRD00683 CAS Registry Number 128196-01-0 |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |